亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Alpha 1 Antitrypsin Treatment during Human Ex Vivo Lung Perfusion Improves Lung Function by Protecting Lung Endothelium

肺 离体 内皮 灌注 体内 医学 肺功能 药理学 心脏病学 生物 内科学 生物技术
作者
A. Mariscal,Antti I. Nykänen,Jussi Tikkanen,A. Ali,Sahar Soltanieh,Allen Duong,M. Galasso,S. Juvet,Tereza Martinu,Marcelo Cypel,M. Liu,Shaf Keshavjee
出处
期刊:Journal of Heart and Lung Transplantation [Elsevier BV]
卷期号:39 (4): S71-S72 被引量:8
标识
DOI:10.1016/j.healun.2020.01.1282
摘要

Purpose The majority of potential donor lungs are not being used. The primary reason for underutilization is the concern for primary graft dysfunction (PGD). There is currently no clinically available therapy for PGD. Alpha 1 antitrypsin (A1AT) is a serine protease inhibitor with anti-inflammatory and cytoprotective properties. We and others have shown benefits of A1AT in small and large animal lung transplant studies. Before performing clinical trials, evidence of therapeutic efficacy in human lungs would be valuable. We tested the effect of A1AT given during ex vivo lung perfusion (EVLP) to human lungs rejected for transplantation. Methods Double lung blocks rejected for transplantation (n=8) were divided and placed on separate EVLP circuits for 12h. Lungs were randomly assigned to receive A1AT or placebo, with the contralateral lung serving as control for the treated lung. Outcome measures included: hourly physiologic lung function, perfusate loss, wet-dry weight ratio, inflammatory mediators, endothelin-1 (ET-1), and zonula occludens tight junction protein‐1 (ZO‐1, immunofluorescence staining). Results The A1AT-treated group demonstrated significantly better lung function: higher pO2 and compliance (Fig A), lower pulmonary artery pressure (-0.4 mmHg p= 0.04) and vascular resistance (-30.4 dynes·s cm−5 p= 0.01). Perfusate loss, a surrogate for lung permeability, was lower in the A1AT group, as was the wet-dry ratio (Fig B). A1AT also decreased ET-1 levels in perfusate (Fig C) and increased ZO-1 expression on endothelial cells (Fig D). Conclusion In this study we demonstrated that human A1AT was able to improve the quality of severly injuried human lungs, likely through endothelial cell protection. The encouraging results justify a clinical trial, in order to improve donor lung quality and clinical outcomes in lung transplantation. Our study also illustrates that testing selected drugs on injured human lungs on EVLP is a viable strategy prior to clinical application. The majority of potential donor lungs are not being used. The primary reason for underutilization is the concern for primary graft dysfunction (PGD). There is currently no clinically available therapy for PGD. Alpha 1 antitrypsin (A1AT) is a serine protease inhibitor with anti-inflammatory and cytoprotective properties. We and others have shown benefits of A1AT in small and large animal lung transplant studies. Before performing clinical trials, evidence of therapeutic efficacy in human lungs would be valuable. We tested the effect of A1AT given during ex vivo lung perfusion (EVLP) to human lungs rejected for transplantation. Double lung blocks rejected for transplantation (n=8) were divided and placed on separate EVLP circuits for 12h. Lungs were randomly assigned to receive A1AT or placebo, with the contralateral lung serving as control for the treated lung. Outcome measures included: hourly physiologic lung function, perfusate loss, wet-dry weight ratio, inflammatory mediators, endothelin-1 (ET-1), and zonula occludens tight junction protein‐1 (ZO‐1, immunofluorescence staining). The A1AT-treated group demonstrated significantly better lung function: higher pO2 and compliance (Fig A), lower pulmonary artery pressure (-0.4 mmHg p= 0.04) and vascular resistance (-30.4 dynes·s cm−5 p= 0.01). Perfusate loss, a surrogate for lung permeability, was lower in the A1AT group, as was the wet-dry ratio (Fig B). A1AT also decreased ET-1 levels in perfusate (Fig C) and increased ZO-1 expression on endothelial cells (Fig D). In this study we demonstrated that human A1AT was able to improve the quality of severly injuried human lungs, likely through endothelial cell protection. The encouraging results justify a clinical trial, in order to improve donor lung quality and clinical outcomes in lung transplantation. Our study also illustrates that testing selected drugs on injured human lungs on EVLP is a viable strategy prior to clinical application.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
vfdhjng完成签到,获得积分20
1秒前
1秒前
可爱的函函的应助被lx采纳,获得10
3秒前
4秒前
华仔的应助被怡宝采纳,获得10
5秒前
summerer发布了新的文献求助20
6秒前
7秒前
嘻嘻哈哈的应助被Gloria采纳,获得10
7秒前
费洛蒙漩涡完成签到,获得积分10
8秒前
孤独孤风完成签到,获得积分10
8秒前
苹果颖完成签到,获得积分10
9秒前
lx完成签到,获得积分10
10秒前
11秒前
11秒前
科研通AI6.4的应助被殷宵箫采纳,获得10
11秒前
12秒前
鱼鱼鱼完成签到,获得积分10
14秒前
lx发布了新的文献求助10
16秒前
16秒前
顺心尔冬完成签到,获得积分10
16秒前
17秒前
康子浩发布了新的文献求助10
17秒前
cong发布了新的文献求助10
19秒前
科研通AI6.2的应助被追寻芷采纳,获得10
21秒前
vfdhjng关注了科研通微信公众号
23秒前
七七完成签到,获得积分10
25秒前
25秒前
礼拜一发布了新的文献求助10
29秒前
淮安石河子完成签到 ,获得积分10
30秒前
坚强含烟完成签到,获得积分10
35秒前
39秒前
江流儿完成签到,获得积分10
41秒前
44秒前
matrixu发布了新的文献求助10
44秒前
ppp发布了新的文献求助10
47秒前
bkagyin的应助被礼拜一采纳,获得10
48秒前
领导范儿的应助被xwz2025采纳,获得10
48秒前
xwz2025完成签到,获得积分20
56秒前
59秒前
1分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Hidden Empire of Finance: How Wall Street Profits from Our Cities and Fuels Global Inequality 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8165846
求助须知:如何正确求助?哪些是违规求助? 9559318
关于积分的说明 21749858
捐赠科研通 7756681
什么是DOI,文献DOI怎么找? 3429083
关于科研通互助平台的介绍 2553354
邀请新用户注册赠送积分活动 2473622